Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma.

Kichenadasse G, Hughes JH, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ.

Cancer Chemother Pharmacol. 2019 Nov 30. doi: 10.1007/s00280-019-04002-1. [Epub ahead of print]

PMID:
31786653
2.

Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202.

Korprasertthaworn P, Chau N, Nair PC, Rowland A, Miners JO.

Biochem Pharmacol. 2019 Nov;169:113616. doi: 10.1016/j.bcp.2019.08.018. Epub 2019 Aug 22.

PMID:
31445021
3.

Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity.

van Dyk M, Miners JO, Marshall JC, Wood LS, Hopkins A, Sorich MJ, Rowland A.

Eur J Clin Pharmacol. 2019 Sep;75(9):1211-1218. doi: 10.1007/s00228-019-02682-5. Epub 2019 May 23.

PMID:
31123759
4.

Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4.

Nair PC, McKinnon RA, Miners JO.

Drug Metab Dispos. 2019 Jun;47(6):616-631. doi: 10.1124/dmd.118.085167. Epub 2019 Mar 22.

PMID:
30902802
5.

Drug and Chemical Glucosidation by Control Supersomes and Membranes from Spodoptera frugiperda (Sf) 9 Cells: Implications for the Apparent Glucuronidation of Xenobiotics by UDP-glucuronosyltransferase 1A5.

Chau N, Kaya L, Lewis BC, Mackenzie PI, Miners JO.

Drug Metab Dispos. 2019 Mar;47(3):271-278. doi: 10.1124/dmd.118.084947. Epub 2018 Dec 12.

PMID:
30541877
6.

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.

Daly AK, Rettie AE, Fowler DM, Miners JO.

J Pers Med. 2017 Dec 28;8(1). pii: E1. doi: 10.3390/jpm8010001. Review.

7.

Response to in vitro and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin.

Miners JO, Pattanawongsa A, Rowland A.

Br J Clin Pharmacol. 2018 Feb;84(2):392-393. doi: 10.1111/bcp.13443. Epub 2017 Nov 3. No abstract available.

8.

A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study protocol.

Currow D, Watts GJ, Johnson M, McDonald CF, Miners JO, Somogyi AA, Denehy L, McCaffrey N, Eckert DJ, McCloud P, Louw S, Lam L, Greene A, Fazekas B, Clark KC, Fong K, Agar MR, Joshi R, Kilbreath S, Ferreira D, Ekström M; Australian national Palliative Care Clinical Studies Collaborative (PaCCSC).

BMJ Open. 2017 Jul 17;7(7):e018100. doi: 10.1136/bmjopen-2017-018100.

9.

The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance.

Miners JO, Yang X, Knights KM, Zhang L.

Clin Pharmacol Ther. 2017 Sep;102(3):436-449. doi: 10.1002/cpt.757. Epub 2017 Jul 26.

PMID:
28599065
10.

Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.

Miners JO, Chau N, Rowland A, Burns K, McKinnon RA, Mackenzie PI, Tucker GT, Knights KM, Kichenadasse G.

Biochem Pharmacol. 2017 Apr 1;129:85-95. doi: 10.1016/j.bcp.2017.01.002. Epub 2017 Jan 6.

PMID:
28065859
11.

Advances in drug metabolism and pharmacogenetics research in Australia.

Mackenzie PI, Somogyi AA, Miners JO.

Pharmacol Res. 2017 Feb;116:7-19. doi: 10.1016/j.phrs.2016.12.008. Epub 2016 Dec 9. Review.

PMID:
27956261
12.

In Vitro Drug Metabolism Using Liver Microsomes.

Knights KM, Stresser DM, Miners JO, Crespi CL.

Curr Protoc Pharmacol. 2016 Sep 16;74:7.8.1-7.8.24. doi: 10.1002/cpph.9.

PMID:
27636111
13.

Haemodynamic effects of parenteral vs. enteral paracetamol in critically ill patients: a randomised controlled trial.

Kelly SJ, Moran JL, Williams PJ, Burns K, Rowland A, Miners JO, Peake SL.

Anaesthesia. 2016 Oct;71(10):1153-62. doi: 10.1111/anae.13562.

14.

Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.

Rowland A, van Dyk M, Mangoni AA, Miners JO, McKinnon RA, Wiese MD, Rowland A, Kichenadasse G, Gurney H, Sorich MJ.

Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):31-49. Epub 2016 Sep 1. Review.

PMID:
27561659
15.

A Fragment-Based Approach for the Computational Prediction of the Nonspecific Binding of Drugs to Hepatic Microsomes.

Nair PC, McKinnon RA, Miners JO.

Drug Metab Dispos. 2016 Nov;44(11):1794-1798. Epub 2016 Aug 19.

PMID:
27543205
16.

A novel approach for the simultaneous quantification of 18 small molecule kinase inhibitors in human plasma: A platform for optimised KI dosing.

van Dyk M, Miners JO, Kichenadasse G, McKinnon RA, Rowland A.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:17-26. doi: 10.1016/j.jchromb.2016.07.046. Epub 2016 Jul 26.

PMID:
27521531
17.

Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2: implications for cancer therapy.

Lewis BC, Korprasertthaworn P, Miners JO.

Pharmacogenet Genomics. 2016 Oct;26(10):453-61. doi: 10.1097/FPC.0000000000000236.

PMID:
27428168
18.

In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes.

Bendikov MY, Miners JO, Simpson BS, Elliot DJ, Semple SJ, Claudie DJ, McKinnon RA, Gillam EMJ, Sykes MJ.

Xenobiotica. 2017 Jun;47(6):461-469. doi: 10.1080/00498254.2016.1203041. Epub 2016 Jul 14.

PMID:
27412850
19.

Cytochrome P450 structure-function: insights from molecular dynamics simulations.

Nair PC, McKinnon RA, Miners JO.

Drug Metab Rev. 2016 Aug;48(3):434-52. doi: 10.1080/03602532.2016.1178771. Epub 2016 May 10. Review.

PMID:
27167388
20.

Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance.

Knights KM, Spencer SM, Fallon JK, Chau N, Smith PC, Miners JO.

Br J Clin Pharmacol. 2016 Jun;81(6):1153-64. doi: 10.1111/bcp.12889. Epub 2016 Mar 14.

21.
22.

Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling.

Lewis BC, Nair PC, Heran SS, Somogyi AA, Bowden JJ, Doogue MP, Miners JO.

Pharmacogenet Genomics. 2016 Jan;26(1):44-50. doi: 10.1097/FPC.0000000000000184.

PMID:
26513304
23.

The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes.

Burns K, Nair PC, Rowland A, Mackenzie PI, Knights KM, Miners JO.

Drug Metab Dispos. 2015 Dec;43(12):1934-7. doi: 10.1124/dmd.115.065292. Epub 2015 Oct 6.

PMID:
26443648
24.

In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism.

Korprasertthaworn P, Polasek TM, Sorich MJ, McLachlan AJ, Miners JO, Tucker GT, Rowland A.

Drug Metab Dispos. 2015 Nov;43(11):1806-14. doi: 10.1124/dmd.115.064790. Epub 2015 Sep 1.

PMID:
26329789
25.

Insights into the UDP-sugar selectivities of human UDP-glycosyltransferases (UGT): a molecular modeling perspective.

Nair PC, Meech R, Mackenzie PI, McKinnon RA, Miners JO.

Drug Metab Rev. 2015 Aug;47(3):335-45. doi: 10.3109/03602532.2015.1071835. Epub 2015 Aug 3. Review.

PMID:
26289097
26.

Insights into the UDP-sugar selectivities of human UDP-glycosyltransferases (UGT): a molecular modeling perspective.

Nair PC, Meech R, Mackenzie PI, McKinnon RA, Miners JO.

Drug Metab Rev. 2015 Aug 3:1-11. [Epub ahead of print]

PMID:
26234632
27.

Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions.

Pattanawongsa A, Chau N, Rowland A, Miners JO.

Drug Metab Dispos. 2015 Oct;43(10):1468-76. doi: 10.1124/dmd.115.065870. Epub 2015 Jul 15.

PMID:
26180128
28.

Characterization of the comparative drug binding to intra- (liver fatty acid binding protein) and extra- (human serum albumin) cellular proteins.

Rowland A, Hallifax D, Nussio MR, Shapter JG, Mackenzie PI, Brian Houston J, Knights KM, Miners JO.

Xenobiotica. 2015;45(10):847-57. doi: 10.3109/00498254.2015.1021403. Epub 2015 Mar 24.

PMID:
25801059
29.

Molecular dynamics simulations: from structure function relationships to drug discovery.

Nair PC, Miners JO.

In Silico Pharmacol. 2014 Nov 21;2:4. doi: 10.1186/s40203-014-0004-8. eCollection 2014.

30.

Transporter-mediated uptake of UDP-glucuronic acid by human liver microsomes: assay conditions, kinetics, and inhibition.

Rowland A, Mackenzie PI, Miners JO.

Drug Metab Dispos. 2015 Jan;43(1):147-53. doi: 10.1124/dmd.114.060509. Epub 2014 Nov 7.

PMID:
25380805
31.

Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.

Snyder BD, Rowland A, Polasek TM, Miners JO, Doogue MP.

Eur J Clin Pharmacol. 2014 Sep;70(9):1115-22. doi: 10.1007/s00228-014-1716-8. Epub 2014 Jul 17.

PMID:
25028073
32.

Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

Barnes KJ, Rowland A, Polasek TM, Miners JO.

Eur J Clin Pharmacol. 2014 Sep;70(9):1097-106. doi: 10.1007/s00228-014-1709-7. Epub 2014 Jun 24.

PMID:
24954688
33.

Enzyme kinetics of uridine diphosphate glucuronosyltransferases (UGTs).

Zhou J, Miners JO.

Methods Mol Biol. 2014;1113:203-28. doi: 10.1007/978-1-62703-758-7_11.

PMID:
24523115
34.

Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies.

Chau N, Elliot DJ, Lewis BC, Burns K, Johnston MR, Mackenzie PI, Miners JO.

J Pharmacol Exp Ther. 2014 Apr;349(1):126-37. doi: 10.1124/jpet.113.212258. Epub 2014 Jan 23.

PMID:
24459244
35.

Generation, validation, and application of a P450 homology model.

Lewis BC, Miners JO.

Curr Top Med Chem. 2013;13(18):2233-40. Review.

PMID:
24047137
36.

Mass or molar? Recommendations for reporting concentrations of therapeutic drugs.

Jones GR, Bryant S, Fullinfaw R, Ilett K, Miners JO, Morris RG, Doogue MP.

Med J Aust. 2013 Apr 15;198(7):368-9.

PMID:
23581955
37.

The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs.

Uchaipichat V, Suthisisang C, Miners JO.

Drug Metab Dispos. 2013 Jun;41(6):1273-84. doi: 10.1124/dmd.113.051656. Epub 2013 Apr 3.

PMID:
23554428
38.

The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification.

Rowland A, Miners JO, Mackenzie PI.

Int J Biochem Cell Biol. 2013 Jun;45(6):1121-32. doi: 10.1016/j.biocel.2013.02.019. Epub 2013 Mar 7. Review.

PMID:
23500526
39.

Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).

Knights KM, Rowland A, Miners JO.

Br J Clin Pharmacol. 2013 Oct;76(4):587-602. doi: 10.1111/bcp.12086. Review.

40.

Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity.

Korprasertthaworn P, Rowland A, Lewis BC, Mackenzie PI, Yoovathaworn K, Miners JO.

Biochem Pharmacol. 2012 Dec 1;84(11):1511-21. doi: 10.1016/j.bcp.2012.08.026. Epub 2012 Sep 5.

PMID:
22981363
41.

Identification of residues that confer sugar selectivity to UDP-glycosyltransferase 3A (UGT3A) enzymes.

Meech R, Rogers A, Zhuang L, Lewis BC, Miners JO, Mackenzie PI.

J Biol Chem. 2012 Jul 13;287(29):24122-30. doi: 10.1074/jbc.M112.343608. Epub 2012 May 23.

42.

Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.

Wattanachai N, Tassaneeyakul W, Rowland A, Elliot DJ, Bowalgaha K, Knights KM, Miners JO.

Drug Metab Dispos. 2012 May;40(5):982-9. doi: 10.1124/dmd.111.044057. Epub 2012 Feb 13.

PMID:
22331994
43.

The glycosidation of xenobiotics and endogenous compounds: versatility and redundancy in the UDP glycosyltransferase superfamily.

Meech R, Miners JO, Lewis BC, Mackenzie PI.

Pharmacol Ther. 2012 May;134(2):200-18. doi: 10.1016/j.pharmthera.2012.01.009. Epub 2012 Feb 1. Review.

PMID:
22322248
44.

Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1.

Polasek TM, Doogue MP, Miners JO.

Ther Adv Drug Saf. 2011 Dec;2(6):253-61. doi: 10.1177/2042098611422559. Review.

45.

Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity.

Knights KM, Mangoni AA, Miners JO.

Expert Rev Clin Pharmacol. 2010 Nov;3(6):769-76. doi: 10.1586/ecp.10.120.

PMID:
22111779
46.

Homodimerization of UDP-glucuronosyltransferase 2B7 (UGT2B7) and identification of a putative dimerization domain by protein homology modeling.

Lewis BC, Mackenzie PI, Miners JO.

Biochem Pharmacol. 2011 Dec 15;82(12):2016-23. doi: 10.1016/j.bcp.2011.09.007. Epub 2011 Sep 14.

PMID:
21930117
47.

Application of homology modeling to generate CYP1A1 mutants with enhanced activation of the cancer chemotherapeutic prodrug dacarbazine.

Lewis BC, Mackenzie PI, Miners JO.

Mol Pharmacol. 2011 Nov;80(5):879-88. doi: 10.1124/mol.111.072124. Epub 2011 Aug 4.

PMID:
21816953
48.

Application of the fluorescent probe 1-anilinonaphthalene-8-sulfonate to the measurement of the nonspecific binding of drugs to human liver microsomes.

McLure JA, Birkett DJ, Elliot DJ, Williams JA, Rowland A, Miners JO.

Drug Metab Dispos. 2011 Sep;39(9):1711-7. doi: 10.1124/dmd.111.039354. Epub 2011 May 24.

PMID:
21610127
49.

Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation.

Uchaipichat V, Raungrut P, Chau N, Janchawee B, Evans AM, Miners JO.

Drug Metab Dispos. 2011 Aug;39(8):1324-8. doi: 10.1124/dmd.111.039727. Epub 2011 May 6.

PMID:
21551257
50.

What's in a name?

Tucker GT, Miners JO.

Br J Clin Pharmacol. 2011 May;71(5):785-6; author reply 787-90. doi: 10.1111/j.1365-2125.2010.03817.x. No abstract available.

Supplemental Content

Loading ...
Support Center